The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from alzheimer's disease-like pathological features

Neurodegenerative Diseases

Volumn 12, Issue 1, 2013, Pages 51-58

  Ghosal, Kaushik ^a   Stathopoulos, Andrea ^a   Thomas, Dustin ^a   Phenis, David ^a   Vitek, Michael P ^b,c   Pimplikar, Sanjay W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Optimal Screening Vehicles Division   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Amyloid precursor protein intracellular domain; Apolipoprotein E; Neurogenesis; Neuroinflammation; Tau

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CENTRAL NERVOUS SYSTEM AGENTS; COG 112; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; DRUG EFFECT; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ADULT; ANIMAL CELL; CONTROLLED STUDY; DENDRITE; FEMALE; MALE; NEUROPROTECTION; PROTEIN DOMAIN; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; FEMALE; GLIOSIS; HIPPOCAMPUS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROGENESIS; PEPTIDES; PHOSPHORYLATION; TAU PROTEINS;

EID: 84879418060     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000341299     Document Type: Article

References (36)

1. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185
2. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH: Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010; 30: 14946-14954
3. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW: Alzheimer's diseaselike pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA 2009; 106: 18367-18372
4. Ghosal K, Stathopoulos A, Pimplikar SW: APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 2010; 5:e11866
5. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA: Neuroinflammation - An early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 2010; 7: 38-41
6. Breitner JC: Epidemiologic clues to the causes and routes to prevention of Alzheimer disease. J Neural Transm Suppl 2000; 59: 251- 254
7. Szekely CA, Green RC, Breitner JC, Ostbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP: No advantage of a beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008; 70: 2291-2298
8. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68: 1800-1808
9. Price DL, Tanzi RE, Borchelt DR, Sisodia SS: Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 1998; 32: 461-493
10. Pimplikar SW: Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009; 41: 1261-1268
11. Ghosal K, Pimplikar SW: Aging and excitotoxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice. Neurobiol Aging 2011; 32: 2320.e1-2320.e9
12. Monje ML, Toda H, Palmer TD: Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760-1765
13. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ: In vivo imaging of microglial activation with [11C] (R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 2006; 21: 89-93
14. Verghese PB, Castellano JM, Holtzman DM: Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011; 10: 241-252
15. Laskowitz DT, Fillit H, Yeung N, Toku K, Vitek MP: Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease. Acta Neurol Scand Suppl 2006; 185: 15-20
16. Laskowitz DT, Goel S, Bennett ER, Matthew WD: Apolipoprotein E suppresses glial cell secretion of tnf alpha. J Neuroimmunol 1997; 76: 70-74
17. Misra UK, Adlakha CL, Gawdi G, McMillian MK, Pizzo SV, Laskowitz DT: Apolipoprotein E and mimetic peptide initiate a calcium- dependent signaling response in macrophages. J Leukoc Biol 2001; 70: 677-683
18. Ryan KA, Pimplikar SW: Activation of GSK- 3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol 2005; 171: 327-335
19. Goodger ZV, Rajendran L, Trutzel A, Kohli BM, Nitsch RM, Konietzko U: Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci 2009; 122: 3703-3714
20. Taupin P: Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells. Int J Med Sci 2008; 5: 127- 132
21. Lazarov O, Mattson MP, Peterson DA, Pimplikar SW, van Praag H: When neurogenesis encounters aging and disease. Trends Neurosci 2010; 33: 569-579
22. Metcalfe MJ, Figueiredo-Pereira ME: Relationship between tau pathology and neuroinflammation in Alzheimer's disease. Mt Sinai J Med 2010; 77: 50-58
23. Wang H, Durham L, Dawson H, Song P, Warner DS, Sullivan PM, Vitek MP, Laskowitz DT: An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. Neuroscience 2007; 144: 1324-1333
24. Laskowitz DT, McKenna SE, Song P, Wang H, Durham L, Yeung N, Christensen D, Vitek MP: COG1410, a novel apolipoprotein Ebased peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma 2007; 24: 1093-1107
25. Vitek MP, Christensen DJ, Wilcock D, Davis J, Van Nostrand WE, Li FQ, Colton CA: APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics. Neurodegener Dis 2012; 10: 122-126
26. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F, Colton CA, Vitek MP: Apolipoprotein E and peptide mimetics modulate inflammation by binding the set protein and activating protein phosphatase 2a. J Immunol 2011; 186: 2535-2542
27. Madeira A, Pommet JM, Prochiantz A, Allinquant B: SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. FASEB J 2005; 19: 1905-1907
28. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-1015
29. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI: Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial alzheimer disease mutations. Arch Neurol 2012; 69: 96-104
30. Ray S, Britschgi M, Herbert C, Takeda- Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss- Coray T: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362
31. in t'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521
32. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ: Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010; 75: 1203-1210
33. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D: LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2011; 7: 56.
34. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM: Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25: 8843-8853
35. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT: Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68: 19-31
36. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM: Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 2011; 187: 6539-6549.